Moderate to Severe Plaque Psoriasis in Children and in Adults with High-Impact Site Involvement Transcript

Psoriasis Uncovered: Episode 273

Release date: March 31, 2026

“Welcome to this episode of “Psoriasis Uncovered”, a podcast series produced by the National Psoriasis Foundation, the nation’s leading organization for individuals living with psoriasis and psoriatic arthritis. Join us to hear our guest speakers uncover topics that lead to a better understanding of the disease and management, to coping and thriving with psoriasis and psoriatic arthritis.”

0:23 EPISODE INTRODUCTION by moderator Kaitlin: My name is Kaitlin, and I'll be your moderator for today's episode, where we're focusing on the impact of plaque psoriasis on children living with the disease and in adults with plaques in high-impact sites, two areas where patients face significant challenges. This episode contains information about studies and a product offered by Johnson & Johnson. I'm here today with Dr Candrice Heath, a dermatologist board-certified in pediatrics, dermatology, and pediatric dermatology, and Carolyn, an NPF volunteer and active mom of two who has been living with plaque psoriasis since childhood. Today, we will hear about their experiences, which could be of interest for parents of children who may be unsure how to help with moderate to severe plaque psoriasis, as well as the physical impacts of plaque psoriasis, and when to consider treating an immune-mediated disease like plaque psoriasis with a biologic.  

1:22 Kaitlin: TREMFYA® (guselkumab) is a prescription medicine used to treat adults and children 6 years and older who also weigh at least 88 lbs or 40 kilograms with moderate to severe plaque psoriasis, who may benefit from taking injections or pills, which are called systemic therapy, or phototherapy, which is treatment using ultraviolet or UV light. In 2 medical studies, 7 out of 10 patients saw at least 90% clearer skin at 16 weeks. Results may vary. TREMFYA® is also prescription medication used to treat adults and children 6 years and older who also weigh at least 88 lbs or 40 kilograms with active psoriatic arthritis. In two medical studies, more than 5 out of 10 adults treated with TREMFYA® had at least a 20% improvement in active PsA symptoms (joint pain, stiffness, swelling) at 24 weeks compared to placebo. Results may vary.   

2:25 Kaitlin: TREMFYA® is not for everyone. Only your healthcare provider can decide if it's right for you. Do not use if you're allergic to TREMFYA®. TREMFYA® is a prescription medication that may cause serious side effects, including serious allergic reactions, infections, and liver problems. TREMFYA® affects your immune system. It may increase your risk of infections and lower your ability to fight them. Please read the Important Safety Information and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your healthcare provider. 

3:03 Q1 Kaitlin: Welcome, Dr Heath and Carolyn. It's a pleasure to have you on Psoriasis Uncovered. To start, let's help our listeners learn a bit more about you. Please introduce yourselves. Dr Heath, let's start with you. 

3:16 Q1 Dr Heath: Thank you. I am pleased to be joining you on today's episode. My name is Dr Candrice Heath and I'm a triple board-certified dermatologist specializing in both adults and pediatric care at Howard University in Washington, DC, and I'm very deeply passionate about clinical research and dedicated to addressing the unique needs of all of my patients, with a particular focus on really supporting vulnerable groups such as children and people with skin of color. Thanks for having me. 

3:48 Q1 Carolyn: It's great for me to be here, too. My name is Carolyn. I'm a National Psoriasis Foundation volunteer, and I have been living with plaque psoriasis since around the age of 11, when I began to see odd patches on my skin, and my arms and my legs, and my scalp. So, like many people living with plaque psoriasis, I had a lot of misdiagnoses, treatment trials and errors. Then, when I was around 30 years old, I started to develop symptoms of active psoriatic arthritis. And being a patient advocate allows me to share my personal experiences to empower others living with psoriatic disease to advocate for their own care. As a part-time teacher, I'm also passionate about knowledge-sharing, so I'm always eager to offer valuable patient perspectives to the healthcare community, and I look forward to sharing my story with everyone listening. 

4:36 Q2 Kaitlin: Thank you both, and we're so happy to have you here today. Like you, Carolyn, I first started experiencing symptoms of plaque psoriasis as a child, and I really struggled to balance being a kid while living with the disease. It can be very difficult. Carolyn, can you tell us about your own journey growing up with psoriasis? How were you first diagnosed, and what was that initial experience like for you? 

4:58 Q2 Carolyn: Yeah, of course. I totally understand. As I mentioned earlier, I first saw plaques of psoriasis around 11 years old, when I started getting itchy, scaly plaques around my elbows, my shins, my knees. And then, they got progressively worse over time, until I reached a point where they were beginning to cover a large part of my body when I was in my 20s. Back in middle school and high school, I wasn't doing much to help manage the symptoms, mainly because I couldn't get the right diagnosis. I was told it was things like rainworm or scabies, but never plaque psoriasis. And as a result, I was prescribed antibiotics or told to use soaps and lotions that didn't actually treat the underlying cause of my disease. As you can imagine, having a highly visible disease that makes you look different from the other kids around you is very tough. Kids would often ask me what kind of bug bites I had – my plaques, that's what they thought they were – or if they were contagious. And since I was misdiagnosed with ringworm and scabies, which are contagious, I actually would avoid close contact with other children. You can imagine how devastating that is for a young kid. I felt like a bother to others. So when I was finally diagnosed correctly with plaque psoriasis, I was relieved to be able to finally have an answer that when other kids asked me about my skin, I could know that it was absolutely not contagious, and having that clarity was a turning point in managing my chronic disease. 

6:17 Q3 Kaitlin: Thank you. I went through a very similar experience. Dr Heath, you specialize in pediatric dermatology. Can you tell us more about plaque psoriasis in children and adolescents and if you have encountered similar stories to Carolyn's in your practice?  

6:31 Q3 Dr Heath: Unfortunately, Carolyn's story is very similar to what I hear often in my practice. Psoriasis affects a lot of people. It affects 8 million people in the United States, and about one in three of those living with psoriasis began to see symptoms when they were just children. This can be especially difficult, because plaque psoriasis can cause children and teens to feel isolated, and it can disrupt their childhood, creating challenges. This can really take a toll not only on the kids, but on the parents as well, who of course want to see their children's skin get better, but really kind of struggle to get the answers that they need, or sometimes are just unsure about what treatment approach might be best for their child. And as Carolyn shared, it's not always easy to get those answers because of a delayed diagnosis. Sometimes we see pediatric psoriasis get confused with conditions, that can look similar at first, like eczema or diaper rash. And as a result, a lot of children may initially be prescribed treatment options that don't truly address the root cause of the disease. Even though plaque psoriasis appears on the skin's surface, it's actually triggered by an overactive immune system, which causes the skin to produce new cells too quickly, resulting in those thick, scaly plaques that we see on the skin. And that's why biologics can be very helpful in treating moderate to severe plaque psoriasis. With these advances in therapies, we can target the inflammatory pathways and help reduce the appearance of plaques and relieve the symptoms. 

8:14 Q4 Kaitlin: As someone who had a difficult treatment journey in childhood using painful products like hot oil and tar on my skin, I completely understand the desire to find other treatment options. Carolyn, what advice would you give parents who are navigating this now with their children?  

8:30 Q4 Carolyn: Yeah, of course. So after having gone through this in my own childhood and as a parent myself now, my advice to parents would be to continually push for answers and don't be afraid to ask why. If something isn't working and your child isn't seeing improvement, discuss it with your child's dermatologist or primary care physician. It's important to push for the best care possible. Similar to your story that you were sharing, even after I had received a diagnosis of plaque psoriasis, some of my initial treatments were not sustainable or in some cases even correct, just due to lack of awareness around plaque psoriasis at the time. For example, the plaques on my toenails were not being treated as psoriasis at first, they were being treated as fungus, and so my toenails were even shaved down so that the medication could get closer to my skin. And not only was this painful, but it was worsening the condition of my plaque psoriasis there. So because of that, I have learned to speak up when my treatment regimen is not doing enough for me. It's OK to look for alternative options if you're not getting results and if topicals are not working. I wouldn't hesitate to consider other treatment options, including biologics. 

9:37 Q4A Kaitlin: And Dr Heath, can you shed light on how you address these concerns with your pediatric patients and their parents? 

9:43 Q4A Dr Heath: I agree. It's important that parents really keep an open dialogue with me, and their feelings and even their children's feelings and expectations about the treatment plan. Because, you know, really, truly there's no one-size-fits-all approach to managing the disease. And individual treatment plans really vary widely based on several factors, such as the severity of the psoriasis or the location of the plaques, and even the age of the patient. Initial lines of therapy like topicals work for some patients. But I've also seen this approach come with practical adherence challenges for kids due to their schedule and everything that goes on with them. And that's why I make sure to thoroughly review all of the treatment options with families facing this chronic disease, including more advanced options like biologics. I explain that they can safely and effectively treat moderate to severe plaque psoriasis from the inside out, and then we align on the best path forward together. The good news is, we do have a number of tools in our toolbox, and treatment options are continuing to expand. And in fact, the FDA recently approved TREMFYA®, a biologic therapy also known as guselkumab, for the treatment of children 6 years and older, who also weigh at least 88 lbs, which is 40 kilograms, with moderate to severe plaque psoriasis. The data that supported this approval came from a phase 3 study called PROTOSTAR, which found that over 50% of the children treated with TREMFYA® saw at least 90% clearer skin at Week 16 compared to 16% in the placebo group. There were no new safety signals seen in the children who were in the study, and the safety data were consistent with the known safety profile of TREMFYA®. I have prescribed TREMFYA® to my adult patients for years, and I'm happy that I can now offer it to my pediatric patients 6 years of age and older, weighing at least 88 lbs or 40 kilograms, and their families as a way to help address moderate to severe plaque psoriasis from the inside out.  

12:05 Q5 Kaitlin: Thank you, Dr Heath, for sharing that exciting development. Carolyn, having faced plaque psoriasis since childhood, what has been the most challenging aspect of living with the disease? Can you share how you have learned to cope with it? 

12:19 Q5 Carolyn: Yeah, so my biggest challenge has been finding a treatment that could address all the places that plaque psoriasis appears on my body and provide skin clearance, especially in the harder-to-treat areas like my scalp. Until recently, my plaque psoriasis has always been front and center in my mind. I would always have to make concessions and adjust my lifestyle to fit my psoriasis. For example, in high school, I had plaque psoriasis on my scalp. Treatment options for scalp psoriasis were more limited at the time, and I was using creams and shampoos that sort of helped but weren't convenient. The combination of putting creams in my hair while going through puberty when your skin is already greasy was just not fun at all. So having scalp psoriasis also caused flakes on my shirt that looked like dandruff, and I would wear lighter colored shirts to help camouflage them. Something as simple as choosing what color shirt to wear each day was becoming really stressful. I was nearly covered in plaques around my 20s, and I was trying to manage everything. The plaques on high-impact sites like my scalp, toenails, and bikini area were challenging to treat because of their location, and it was impacting me physically. When I would work out, sweating and wiping my brows became very painful, and joint pain was forcing me to change how and when I exercised. As an active person who loves exercising, you can imagine how difficult all of this was, and so I needed something to change. I started experiencing joint pain around age 28, but it wasn't until I was in my 30s that I really spoke to my doctor and learned that it was active psoriatic arthritis. My doctor considered my active psoriatic arthritis symptoms and my skin plaques and prescribed a biologic. While people do respond differently to treatments, once I was on a biologic, I saw significant improvement in my active psoriatic arthritis symptoms, as well as skin clearance. I was able to get back to some of my daily activities, which I am so grateful for. I'm currently on TREMFYA® and it's working really well for me. In fact, this year my family visited our 50th state together, which was a bucket list item, and we were so excited to be able to accomplish it.  

14:20 Q6 Kaitlin: That's great news, Carolyn. Congratulations on that accomplishment. Dr Heath, can you talk about how you work with your patients to determine their treatment plan, particularly for those who may be in a similar position to Carolyn and have plaques in high-impact sites? 

14:35 Q6 Dr Heath: Absolutely. For far too long, the conversation around plaque psoriasis treatment has been really informed primarily by body surface area, or BSA. If lesions don't cover more than 10% of a patient's body, they're considered to have low BSA and are often prescribed topical treatments as a first line of treatment, regardless of where those lesions are located on the body or their impact on the patient themselves. This means that for those living with low BSA, moderate plaque psoriasis with plaques in high-impact areas like the scalp, nails, or in sensitive genital areas, even smaller lesions that might not be as visible can still cause significant discomfort and pain and interfere with daily activities. As we heard from Carolyn, plaque psoriasis lesions in those areas can negatively impact daily life, but treating them with topical creams or ointments only addresses surface-level symptoms and may not be practical long-term. For example, some high-impact sites absorb topicals more quickly, like the genital folds or locations with thinner skin like around the eyes, makes the skin more susceptible to the adverse effects of topical steroids. So this really often leaves patients with low BSA moderate plaque psoriasis with high-impact site involvement undertreated, despite the significant impact on their lives. Recognizing that skin plaques are just the tip of the iceberg, which is what's visible on the surface, and that more patients with low BSA could potentially benefit from addressing the underlying cause of their inflammation, Johnson & Johnson conducted the SPECTREM clinical trial. The study assessed the efficacy of TREMFYA® in adults with low BSA, meaning 2% to 15% body surface area, with moderate plaque psoriasis with high-impact site involvement, and found that significantly more patients treated with TREMFYA® – 74.2% – achieved complete or nearly complete skin clearance compared to those who received placebo, which was 12.4% at Week 16. Of course, results may vary. The average patient saw over 80% improvement from baseline for both BSA and Psoriasis Area and Severity Index compared to those who received placebo at Week 16. These results give healthcare providers like myself and patients the confidence to choose biologics like TREMFYA® if you have low body surface area moderate plaque psoriasis when appropriate. Of course, biologics may not be the right option for everyone, so you should speak to your doctor, ask about receiving more information. 

17:38 Q7 Kaitlin: What advice do you both have for patients who may be feeling discouraged with their plaque psoriasis or their children's plaque psoriasis and are struggling to find the right treatment? Carolyn, would you like to go first? 

17:49 Q7 Carolyn: Well, knowing what I now know about psoriatic disease, I would encourage my younger self and others on their treatment journey to lean into the support system who accepts you for who you are and makes the effort to understand your disease. For me, it was important to find a doctor who was a great care partner and who works with me to find a treatment option that works for me. Obtaining support and help, especially through the NPF, has been helpful for me. The NPF connected me to valuable resources like patient education materials, advocacy opportunities, and tips for managing daily life with plaque psoriasis. Beyond that, social media channels have broadened my network and provided a sense of community and support. I also really encourage you to do your own research. Dive into the brand websites and look at the pharmaceutical company websites. They often have incredibly detailed information, and resources that can help you truly understand the medication you're taking or considering trying, because I really do think the more informed you are, the better conversations you can have with your doctor.  

18:52 Q7 Dr Heath: That's great advice, Carolyn. And from the dermatologist side, we love when patients come with those notes and questions, because collaboration really is key to finding the right treatment options. My advice based on today's discussion is to explain the full burden of disease to your physician or to your child's physician. Clinical presentation may be misleading. Without more context, as we heard today, especially about high-impact site involvement, it's important. Having this additional context is key to helping us identify the most appropriate treatment plan for our patients. Ensuring my patients understand that their treatment journey is just that – a journey – is really important. Nothing is too small or unimportant to talk to your doctor about, because if it matters to you, it matters to us. The information we shared today suggests that a comprehensive approach, including therapies like TREMFYA®, may help adults and children 6 years and older who also weigh at least 88 lbs, which is 40 kilograms with moderate to severe plaque psoriasis, or, as we discussed, adults who have few plaque psoriasis lesions, but in difficult to treat areas. Biologics are often prescribed when topical treatments and orals can't help patients to address the symptoms. From a clinical perspective, the uniqueness of a biologic is that it targets proteins and cells that play a role in the development of plaque psoriasis, offering a different treatment approach by addressing the disease from the inside out. If you need support with managing moderate to severe plaque psoriasis or talking about treatment options with your doctor, go to TREMFYA.com/doctorguide and download their discussion guide before your next appointment. That way, you're prepared to ask the right questions and have an open and honest conversation about your experience with plaque psoriasis.  

CLOSING comments:  

20:59 Kaitlin: Thank you, Dr Heath and Carolyn, for your insights and for sharing your stories. I'm hopeful that our listeners will come away feeling not only less alone, but empowered to take control of their plaque psoriasis. For our listeners, this sponsored episode was brought to you by Johnson & Johnson. Our dermatologist consultant, Dr Heath, is a paid speaker for Johnson & Johnson. The speakers are presenting on behalf of Johnson & Johnson and must present information in compliance with FDA requirements applicable to Johnson & Johnson. 

21:33 Kaitlin: Please continue listening for Important Safety Information about TREMFYA®, a treatment discussed in today's episode. As a reminder, you can view the Important Safety Information and full Prescribing Information by visiting TREMFYA.com. 

21:48 Indications (ISI) 

What is Tremfya® (guselkumab)?  

TREMFYA® is a prescription medicine used to treat adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light). 

TREMFYA® is a prescription medicine used to treat adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with active psoriatic arthritis. 

TREMFYA® is a prescription medicine used to treat adults with moderately to severely active ulcerative colitis. TREMFYA® is a prescription medicine used to treat adults with moderately to severely active Crohn's disease. 

22:37 Important Safety Information 

What is the most important information I should know about TREMFYA®

TREMFYA® is a prescription medicine that may cause serious side effects, including: 

Serious Allergic Reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction: 

  • fainting, dizziness, feeling lightheaded (low blood pressure) 
  • swelling of your face, eyelids, lips, mouth, tongue or throat
  • trouble breathing or throat tightness 
  • chest tightness 
  • skin rash, hives 
  • itching 

Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: 

  • fever, sweats, or chills 
  • muscle aches 
  • weight loss 
  • cough 
  • warm, red, or painful skin or sores on your body different from your psoriasis 
  • diarrhea or stomach pain 
  • shortness of breath 
  • blood in your phlegm (mucus) 
  • burning when you urinate or urinating more often than normal 

Liver Problems. - With the treatment of Crohn’s disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA®. With the treatment of plaque psoriasis or psoriatic arthritis, your healthcare provider may do blood tests to check your liver before and as necessary during treatment with TREMFYA®. Your healthcare provider may stop treatment with TREMFYA® if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: 

  • unexplained rash 
  • vomiting 
  • tiredness (fatigue) 
  • yellowing of the skin or the whites of your eyes 
  • nausea 
  • stomach pain (abdominal) 
  • loss of appetite 
  • dark urine 

Do not use TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA®

Before using TREMFYA®, tell your healthcare provider about all of your medical conditions, including if you: 

  • have any of the conditions or symptoms listed in the section “What is the most important information I should know about TREMFYA®?” 
  • have an infection that does not go away or that keeps coming back. 
  • have TB or have been in close contact with someone with TB. 
  • have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA®. Children should be brought up to date with all vaccines before starting TREMFYA®
  • are pregnant or plan to become pregnant. It is not known if TREMFYA® can harm your unborn baby. 
  • Pregnancy Registry: If you become pregnant during treatment with TREMFYA®, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA®. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing MotherToBaby@health.ucsd.edu. The purpose of this registry is to collect information about the safety of TREMFYA® during pregnancy. 
  • are breastfeeding or plan to breastfeed. It is not known if TREMFYA® passes into your breast milk. 

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. 

What are the possible side effects of TREMFYA®? 

TREMFYA® may cause serious side effects. See “What is the most important information I should know about TREMFYA®?” 

The most common side effects of TREMFYA® include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, bronchitis, feeling very tired (fatigue), fever (pyrexia), and skin rash (rash). 

These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects. 

Use TREMFYA® exactly as your healthcare provider tells you to use it.

Please read the full Prescribing Information, including Medication Guide, for TREMFYA® and discuss any questions that you have with your doctor. 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. 

Dosage forms and strength 

TREMFYA® is available as 100 mg/mL and 200 mg/2 mL for subcutaneous injection, and as a 200 mg/20 mL (10 mg/mL), single dose vial for intravenous infusion. 

We hope you enjoyed this episode of Psoriasis Uncovered for people living with psoriasis and psoriatic arthritis. If you or someone you love has ever struggled with psoriatic disease, our hope is that through our podcast you’ll gain information that inspires you to lead a healthy life and look to the future. Please share the episode link if the content in today’s episode will benefit someone you know.

You can find this or all future episodes of Psoriasis Uncovered on Apple Podcasts, Spotify, Amazon Music, Gaana, Pandora, iheart radio, and the National Psoriasis Foundation web page. To learn more about this topic or others please visit psoriasis.org or contact us with your questions or comments by email at podcast@psoriasis.org.

Return to the Episode Page

Go to episode

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2026 National Psoriasis Foundation/USA


The National Psoriasis Foundation is a qualified 501(c)(3) EIN 93-0571472.


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.